Two Hour Online Webinar

Previously Recorded

 This 2 Hour Webinar includes a total of 2 CE Credits. The cost of the two hour webinar is $39.99.

To register for the webinar click "BUY IT NOW".

If you have any difficulty registering, please contact us here

 Vax Up or Mask Up! 

Understanding Covid 19 Vaccine Safety and Protective Efficacy

Originally Recorded on September 17, 2021

This new training meets the new DC Covid-19 training requirement.

Do you have questions about the Covid-19 vaccine? Are you unsure of the benefits of the vaccines? Concerned about it's safety? Are you struggling with helping your clients or patients understand the benefits of the vaccines? This new training with vaccine development specialist Dr. Robert Edelman, MD, will answer many of the questions that people have regarding the Covid-19 vaccines.  

Among the topics addressed will be why some people get sicker from Covid than others, and what we know about how long the vaccine lasts. We will also discuss the Delta variant and why it changed our lives suddenly after dealing 17 months with the earlier covid strains. 

What is mRNA and does it affect my DNA? If I already had Covid should I get vaccinated? Do I still need two doses, or maybe just one? This brand new training meets the new DC Covid-19 training requirement. Earn 2 CE credits. 

(Trainer, Dr. Robert Edelman, MD is currently a Professor Emeritus of Medicine on vaccine development at the University of Maryland (UM) Center for Vaccine Development and Global Health (CVD). His projects include the biotechnology industry, major pharmaceutical houses, the World Health Organization (WHO), the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID), the Department of Defense, the U.S. Agency for International Development, and the Gates Foundation's Malaria Vaccine Initiative and Pediatric Dengue Vaccine Initiative.

Dr. Edelman served as the Associate Director for Clinical Research at the CVD from 1988 until 2011 when he became the Associate Director for Regulatory Affairs and Bioethics. Dr. Edelman’s experience includes leading clinical trials for experimental vaccines, licensed vaccines, and biologicals against a variety of infectious diseases for adult and pediatric volunteers. He was the principal investigator for the University of Maryland Immunosenescence/Immunosupression Research Group.

Dr. Edelman is a recognized expert in clinical trials of vaccine adjuvants. He is interviewed and quoted widely on vaccines against bioterror agents, influenza, dengue, and other emerging infections. He was a member of the WHO Advisory Committee on Dengue and other Flavivirus vaccines for five years and directed the Travelers’ Health Clinic at the UM Medical Center for 20 years. Dr. Edelman served as Chairman of the UM Institutional Review Board (IRB) for nine years and ran a mentoring program for the entire faculty of University of Maryland School of Medicine on conducting clinical research. Dr. Edelman has co-edited a book, authored 187 peer-reviewed papers, 29 book chapters, 80 abstracts, and has 13 invited editorials and book reviews.

Dr. Edelman served in both the United States (US) Army and the US Public Health Service (USPHS) prior to joining the faculty at UM. His experiences include investigating the pathogenesis and epidemiology of arbovirus infections, the relationship between malnutrition and immunity, and performing Phase 1 clinical trials for several viral vaccines, including vaccines against the bioterror agents, tularemia and Venezuelan equine encephalomyelitis virus. Dr. Edelman served as Deputy Director of the Microbiology and Infectious Disease Program at NIAID and as Chief of the Clinical and Epidemiological Studies Branch. During this time, his clinical research included Lyme disease, maternal vaginal infections as a cause of low infant birth weight, epidemiology of AIDS, and clinical trials of new antifungal drugs.)

This 120 minute webinar includes a total of 2 CE Credits. The cost of the two hour webinar is $39.99.

Date of CE Release: September 10, 2021
Date of CE Expiration: October 10th, 2025

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CE You!  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Successful completion of this program qualifies for up to 2.00 AMA PRA Category 1 Credit(s)^TM.  Amedco LLC certifies that the attendee named above has participated in the enduring activity titled Vax Up or Mask Up! Understanding Covid-19 Vaccine Safety and Protective Efficacy, online, between September 10, 2021 and September 29, 2023 and is awarded the number of AMA PRA Category 1 Credits^TM listed above.

Physicians (ACCME)
Amedco LLC designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. 

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.